Welichem is Participating in BioPartnering North America Conference in February, 2008

BURNABY, BC, Feb. 1 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce that a team of five delegates from the Company will attend the 6th Annual BioPartnering North America (BPN) Conference, which will be held at the Westin Bayshore Resort and Marina in Vancouver, B.C., Canada on February 4 to 6, 2008.

BPN is North America's most innovative partnering conference for life science innovators and investors, and is supported by leading pharmaceutical, biotechnological, financial and service companies from around the world. It offers one of the best networking opportunities with business development executives and will be attended by over 800 delegates from more than 500 companies.

Welichem will feature an Open House Podium Presentation and one Open House Booth Presentation to showcase its two promising drug candidates. WBI-1001, a unique anti-inflammatory compound currently in clinical trials, is shown to be effective in treating psoriasis and eczema from its preliminary test results. WBI-2100, on the other hand, has shown strong efficacy in targeting solid tumours as well as in boosting neutrophil level. The Company's team will have face-to-face meetings with over a dozen large pharmaceutical/biotech companies to pursue licensing and partnering opportunities for drug development and commercialization.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements. The Company thus seeks safe harbour.

For further information

York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com

Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com

--------------------------------------------------------------------------------

Source: Welichem Biotech Inc.